secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001438533-24-000022
Event type: other
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve 2.7M share increase under 2018 Equity Plan, re-elect all directors at annual meeting
--------------------------------------------------------------------------------

- All ten director nominees elected; John A. Orwin received 43.7M for vs 14.9M withheld.
- 2018 Equity Plan amended to add 2.7M authorized shares; vote 36.4M for, 22.1M against.
- Advisory say-on-pay passed with 55.8M for, 2.9M against, 42k abstain.
- Ernst & Young ratified as FY2024 auditor with 60.5M for, 2.2M against, 52k abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/tvtx-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001438533-24-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer